Clinical Trials Search Results

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest

Initial search results include only NCI-sponsored clinical trials. To search all trials, click the "REFINE SEARCH" button, scroll down to the Trial ID/Sponsor section and select the "All" check box in the Sponsor of Trial section.

View Content for:
Display:
?
Drug:  pegaspargase
Find trials that include:  Any drugs shown
Trial Status:  Closed
Results 1-25 of 73 for your search:
Start Over
Combination Chemotherapy in Treating Children With Newly Diagnosed Acute Lymphoblastic Leukemia
Phase: Phase III
Type: Treatment
Status: Completed
Age: 1 to 9
Sponsor: NCI, Other
Protocol IDs: 1952, CCG-1952, CDR0000064665, NCT00002744
Comparison of Two Combination Chemotherapy Regimens in Treating Adults With Previously Untreated Leukemia or Lymphoma
Phase: Phase III
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: NCI, Other
Protocol IDs: 96-015, P30CA008748, MSKCC-96015A1, NCI-V96-0881, NCT00002766
Combination Chemotherapy in Treating Children With Acute Lymphocytic Leukemia
Phase: Phase III
Type: Treatment
Status: Completed
Age: 1 to 21
Sponsor: NCI, Other
Protocol IDs: 1961, CCG-1961, CDR0000064953, NCT00002812
Combination Chemotherapy in Treating Children With Relapsed Acute Lymphoblastic Leukemia
Phase: Phase III
Type: Treatment
Status: Completed
Age: under 21
Sponsor: NCI, Other
Protocol IDs: 1951, CCG-1951, CDR0000064968, NCT00002816
Combination Chemotherapy in Treating Children With Acute Lymphoblastic Leukemia
Phase: Phase III
Type: Treatment
Status: Completed
Age: 1 to 9
Sponsor: NCI, Other
Protocol IDs: 9904, COG-P9904, POG-9904, CDR0000067657, NCI-2012-02321, NCT00005585
Combination Chemotherapy in Treating Children With Newly Diagnosed Acute Lymphoblastic Leukemia
Phase: Phase III
Type: Treatment
Status: Closed
Age: 1 to 21 at diagnosis
Sponsor: NCI, Other
Protocol IDs: 9905, COG-P9905, POG-9905, CDR0000067704, NCI-2012-02325, NCT00005596
Comparison of Different Combination Chemotherapy Regimens in Treating Children With Acute Lymphoblastic Leukemia
Phase: Phase III
Type: Biomarker/Laboratory analysis, Treatment
Status: Closed
Age: 1 to 9
Sponsor: NCI, Other
Protocol IDs: 1991, CCG-1991, CDR0000067855, NCI-2012-02333, U10CA98543, COG-C1991, NCT00005945
Pilot Phase III Study of Intensive High-Dose PEG-ASP in Combination Chemotherapy for T-Cell ALL and Lymphoblastic Lymphoma
Phase: Phase III
Type: Treatment
Status: Closed
Age: under 22
Sponsor: NCI
Protocol IDs: POG-9295
Phase III Pilot Study of PRED/VCR/PEG-ASP followed by MTX/MP/CF in Standard-Risk Patients with Acute Lymphocytic Leukemia: Protocol ALinC #16
Phase: Phase III
Type: Treatment
Status: Closed
Age: 1 to 21 years
Sponsor: NCI
Protocol IDs: POG-9202
Pilot Phase III Study of Intensive Multiagent Consolidation with ID MTX/MP and ID MTX/ARA-C with Continuous Alternate-Week PEG-ASP in High-Risk Patients with ALL
Phase: Phase III
Type: Treatment
Status: Completed
Age: 12 months to 21 years
Sponsor: NCI
Protocol IDs: POG-9203
Dexamethasone Compared With Prednisone During Induction Therapy and Methotrexate With or Without Leucovorin During Maintenance Therapy in Treating Patients With Newly Diagnosed High-Risk Acute Lymphoblastic Leukemia
Phase: Phase III
Type: Treatment
Status: Closed
Age: 1 to under 31
Sponsor: NCI, Other
Protocol IDs: AALL0232, COG-AALL0232, CDR0000349182, NCT00075725
Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Acute Lymphoblastic Leukemia
Phase: Phase III
Type: Treatment
Status: Closed
Age: 1 to under 10
Sponsor: NCI, Other
Protocol IDs: AALL0331, NCI-2009-00302, COG-AALL0331, CDR0000409589, U10CA098543, NCT00103285
Low-Dose or High-Dose Vincristine and Combination Chemotherapy in Treating Young Patients With Relapsed B-Cell Acute Lymphoblastic Leukemia
Phase: Phase III
Type: Treatment
Status: Closed
Age: 1 to under 30
Sponsor: NCI, Other
Protocol IDs: AALL0433, NCI-2009-00306, COG-AALL0433, CDR0000495359, U10CA098543, NCT00381680
Treatment of Acute Lymphoblastic Leukemia in Children
Phase: Phase III
Type: Treatment
Status: Closed
Age: 1 to 17
Sponsor: NCI, Other
Protocol IDs: 05-001 / CDR0000513019, P01CA068484, P30CA006516, DFCI-05001, NCT00400946
A Study of Actonel for the Prevention of Bone Loss
Phase: Phase III
Type: Supportive care, Treatment
Status: Completed
Age: 18 and over
Sponsor: Other
Protocol IDs: ID03-0124, NCI-2010-01997, NCT00452439
Dasatinib and Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Acute Lymphoblastic Leukemia
Phase: Phase III
Type: Biomarker/Laboratory analysis, Treatment
Status: Closed
Age: 1 to 30
Sponsor: NCI
Protocol IDs: NCI-2009-00312, CDR0000600217, COG-AALL0622, AALL0622, U10CA098543, NCT00720109
Phase III Randomized Study of Standard Induction Chemotherapy With or Without Nelarabine or Rituximab in Patients With Newly Diagnosed, Previously Untreated Acute Lymphoblastic Leukemia. Note: The information about this trial has not been updated by the sponsor/principal investigator/lead organization. Cancer.gov cannot verify the accuracy of the information.
Phase: Phase III
Type: Supportive care, Treatment
Status: Unknown
Age: 25 to 65
Sponsor: Other
Protocol IDs: UCL-08-0167, UCL/08/0167, EU-21009, EUDRACT-2009-012717-22, UCL-UKALL14, MREC-09-H0711-90, NCRI-UCL-08-0167, CRUK-C27995-A9609, NCT01085617
Combination Chemotherapy in Treating Young Patients With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia or T-cell Lymphoblastic Lymphoma
Phase: Phase III
Type: Behavioral study, Treatment
Status: Closed
Age: 1 to under 31
Sponsor: NCI
Protocol IDs: NCI-2009-00307, CDR0000514500, COG-AALL0434, AALL0434, U10CA098543, NCT00408005
Blinatumomab in Treating Younger Patients With Relapsed B-cell Acute Lymphoblastic Leukemia
Phase: Phase III
Type: Biomarker/Laboratory analysis, Treatment
Status: Temporarily closed
Age: 1 to 30
Sponsor: NCI
Protocol IDs: NCI-2014-00631, COG-AALL1331, AALL1331, U10CA180886, U10CA098543, NCT02101853
Start Over